
Translational safety assessment strategies for bispecific and multispecific antibodies
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxNMmJCMmU0SlFzR0lyR2JtT0tmZllJLS1iUERFZGs0SFF4eGRvbFhETkd0T1llcUtmUzBsUm43YVhfam9ydHBYRFF5dUtaNWtJc0tfM3dMOXZrRXJRZGdsMEVBT3N4YlVTMXA0NC1rV3IwbGd0M3RfVnBvdEZmamRhbHVSc0VKd0tuUHRSVm1BbXppNTVVc2FmN2FvVzhKOV9fYndoNlVpXzM2VlVFZ2RIRDdSYWhkTnhxbV9NRmZrTzBnNy1kbTJkOUFYZTh1dkJNTEQ3dVc3ZkVYZGZfVWwzQjFxNVg?oc=5" target="_blank">Translational safety assessment strategies for bispecific and multispecific antibodies</a>&nbsp;&nbsp;<font color="#6f6f6f">Clarivate</font>
